Examiner Name

Attorney Docket Number

Sheet

of 2

JBA-

UNIMD-4

			U.S. PATENT DOCU	MENTS	
F		U.S. Patent Documen	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant
Examiner Initials	Cite No	Number Kind Code (if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
<u>د۲</u>	A1	5,932,478	Multhoff	8/3/99	
cy-	A2	5,962,424	Hallahan et al	10/5/99	
					DECEME
	i		COPY OF PA		RECEIVED
	!		ORIGINALLY	FILEU	
					MAY 1 3 2002
	I				
					TECH CENTER 1600/29
	 				I ILOH OLIVILIY 1000/20
		ļ			
		<u> </u>			
	1			,	

			FOREIG	N PATENT DOCU	MENTS		
Cdo	Fore	eign Patent Di	ocument	Name of Patentee	Date of Publication of	Pages, Columns, Lines,	I
No.	Office ³	Number ⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T _a
							
			i		i		ļ
							ļ
·							
			- i·· i	· ···			
	Cite	Cite	Cite	Cite No Office Number Kind Code Code Code Code Code Code Code Cod	Cite No Office Number Kind Code or Applicant of	No Office Number Kind Code Or Applicant of Cited Document	Cite No Office Number Kind Code Office Number Relevant Name of Patentee Or Applicant of Cited Document Office Number Relevant Name of Patentee Or Applicant of Cited Document Office Number Relevant Office Number Relevant

Examiner Signature	C	house	DHY	Date Considered	2	(6)	06

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Unique citation designation number ² See attached Kinds of U.S. Patent Documents ³ Enter Office that issued the document, by the two-letter code :WIPO Standard ST 31 ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. * Kind of document by the appropriate symbols as indicated in the document cinder WIPO Standard ST. 16 if possible. * Applicant is 1000 at the kind of document by the appropriate symbols as indicated in the document cinder WIPO Standard ST. 16 if possible. * Applicant is 1000 at the kinder them is English, and date in the kinder them.

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
Patent and Trademark Office U S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no pe spond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of 2

Complete if Known						
Application Number	09/936,565	٦				
Filing Date	February 5, 2002	٦				
First Named Inventor	John J. SAUK	٦				
Group Art Unit	1646 (643	╗				
Examiner Name	TBA- YAEN	٦				
Attorney Docket Number*	UNIMD-4	ナ				

	,	OTHER PRIOR ART NON PATENT LITERATURE DOCUM	IENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (with the item (book, magazine, journal, serial, symposium, catalog, etc.), date number(s), publisher, city and/or country where publisher.	, page(s), volume-issue	T 2
c/	A3	Larocca et al., "Gene transfer to mammalian cells using genetically targeted filamen FASEB Journal, Vol. 13, April 1999, pp. 727-734	stous bactenophage," The	
_ (A4	Database Medline on Dialog, US National Llibrary of Medicine, (Bethesda, MD, U RAZZAQUE et al., "The possible role of colligin/hsp 47, a collagen binding protein in and experimental fibrotic diseases," Histology and Histopathology. October 1999, Vo	the pathogenesis of human	
СУ	A5	Database Medline on Dialog, US National Library of Medicine, (Bethesda, MD, USA), et al. *Cell Surface Colligin/Hsp47 associates with tetraspanin protein CD9 in epiden Journal of cellular Biochemistry, May 1999, Vol. 73, No. 2, pp. 24	No. 1999241927 NORRIS moid carcinoma cell lines.*	
		COPY OF PAPERS	RECEI	VE
		ORIGINALLY FILED	MAY 1 3	2002
			TECH CENTER	1600,29
				

Examiner Signature	Champhil	Date Considered	2_	16	06

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applica it

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement. This form is estimated to take 2.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. U.S. Patent and Trademark. Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box \rightarrow +

PTO/SB/08A (08-00) -

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Attorney Docket Number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 09/936.565 RECEIVED

Filting Date February 4, 2002

First Named Inventor John J. SAUK 0CT 1 7

Group Art Unit 1646 6 43

Examiner Name Unassigned YAEF CH CENTER 1600/2900

UNIMD-4

(use as many sheets as necessary)

Sheet 1 of 1

Substitute for form 1449A/PTO

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	τ2
cΥ		Geng HU et al., "Endoplasmic Reticulum Protein Hsp47 Binds Specifically to the N-Terminal Globular Domain of the Amino-Propeptide of the Procollagen 1 of (I)-Chain," JOURNAL OF CELLULAR BIOCHEMISTRY, Vol. 59, pp. 350-367	
1		Timothy SMITH et al. "Hsp47 And Cyclophilin B Traverse the Endoplasmic Reticulum with Proceilages into Pre- Golgi Intermediate Vesicles, "THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 270, No. 31, Issue of August 4, 1995, pp. 18323-18328	
		Luciano R. FERREIRA et al.," Hsp47 And Other ER-Resident Molecular Chaperones Form Heterocomplexes With Each Other and With Collagen Type IV Chains," CONNECTIVE TISSUE RESEARCH 1996, Vol. 33, No. 4, pp 265-273.	
		Hessam SIAVASH et al., *Inhibition of Cysteine Proteinases by Autolytic Digestion is Mediated by CBP2/Hsp47.* CONNECTIVE TISSUE RESEARCH, Vol. 43, pp. 1-6, 2002.	
		Carla HERBERT et al., "Cell Surface Colligin/Hsp47 Associates With Tetraspanin Protein CD9 in Epidermoid Carcinoma Cell Lines, "JOURNAL OF CELLULAR BIOCHEMISTRY, Vol. 73, pp. 248-258, 1999	_
		Ricardo Della COLETTA et al., "Increase in Expression of Hsp47 And Collagen in Hereditary Gingival Fibromatosis is Modulated by Stress And Terminal Procollagen N-Propeptides," CONNECTIVE TISSUE RESEARCH, Vol. 40(4), pp. 237-249, 1999.	
		Carla HERBERT et al., "Non-Natural CBP2 Binding Peptides and Peptomers Modulate Carcinoma Cell Adhesion and Invasion." JOURNAL OF CELLULAR BIOCHEMISTRY, Vol. 82, pp. 145-154, 2001	
		John J. SAUK et al. "Binding Motifs of CBP2 A Potential Cell Surface Target for Carcinoma Cells." JOURNAL OF CELLULAR BIOCHEMISTRY, Vol. 78, pp. 261-263, 2000	
١		Search Results on HSP47	
CY		Abstract of KOIDE et al. J. BIOL CHEM 2002 February 22, 277(8) 6178-82	

Signature Chrony / Considered 2/16/06	Examiner Signature	priz	Date Considered	2/16	106	
---------------------------------------	-----------------------	------	--------------------	------	-----	--

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. U.S. Patent and Trademark Office. Washington. DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington. DC 20231.

Unique citation designation number . Applicant is to place a check mark here if English language Translation is attached

PTO SB 08A (08-00)

Approved for use through 10 31 2002 OMB 0651-0031

Approved for use through 10 31 2002 OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

ostitute for form 1449A PTO

THADE WAS INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet

	Complete if Known					
Application Number	09/936,565					
Filing Date	February 4, 2002					
First Named Inventor	John J. Sauk					
Group Art Unit	D4 1643					
Examiner Name	Unknewn YAEN					
Attorney Docket Number	UNIMD 4					

			U.S. PA1	TENT DOCUMENTS	
_		U.S. Patent Do			Date of Publication of Cited Document
Examiner Initials	Cite No	Number	Find Code	Name of Patentee or Applicant of Cited Document	MM-DD-YY'YY
miliais	Cité No	710			
	 	· · · —			-1
	+				-
			!	 	
		·			
	 				
					
	<u> </u>				
					i g m
	1				50 M
	-				9
					
	! _ _				
	 				
	1				

				FOREIGI	N PATENT DOCUMENTS			
		, F	oreign Patent Docu			Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No	Office ³	Number*	Find Code* (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	د ا
CY		wo	9729130	T	Desjardins Louise	08-14-1997		
	· — · -	. — ·		1	1			
		i						
		ļ		1				
		• •					•	
	•			• •	• •			
		: .	•	·		•	•	

Examiner Signature Chrus M'X	Date Considered	2/16/06

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Unique dation designation number . See attorned number of C.S. Patent Lacaments. Effect under that issued the decimient of the two after code A.P.C. Standard S.S. (1.3 m. attanese catent of convents the indicate of the use of the respect to the set of the senators be of the

JUN 2 6 2003 Approved for use through 10 31 2002 OMB 0651-0031

U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE apenwork. Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Brown

PTO SB 08A (08-00)

Substitute for form 1449A PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 09/936,565 February 4, 2002 Filing Date John J. Sauk First Named Inventor 1643 Group Art Unit Unknown YAEN **Examiner Name UNIMD 4**

(use as many sheets as necessary)

Attorney Docket Number Sheet

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	т-				
		PATENT ABSTRACTS OF JAPAN, Abstract of JP 07072156, 17 March 1995.					
QY	HU GENG et al., "Endoplasmic reticulum protein Hsp47 binds specifically to the globular domain of the amino-propeptide of the procollagen I alpha-1(I)-chain," Cellular Biochemistry, 1995, pp. 350-367, vol. 59, no. 3.						
(HEBERT CARLA et al., "Cell surface colligin/Hsp47 associates with tetraspanin protein CD9 in epidermoid carcinoma cell lines," Journal of Cellular Biochemistry, 1 May 1999, pp. 248-258, vol. 73, no. 2.					
		MORINO MASAYOSHI et al., "HSP47 as a possible marker for malignancy of tumors in vivo," In Vivo, 1994, pp. 285-288, vol.8, no. 3.					
		MORINO MASAYOSHI et al., "Marked induction of HSP47, a collagen-binding stress protein, during solid tumor formation of ascitic Sarcoma 180 in vivo," In Vivo, 1995, pp. 503-507, vol. 9, no. 5.					
		MORINO MASAYOSHI et al., "Specific expression of HSP47 in human tumor cell lines in vitro," In Vivo, 1997, pp. 17-22, vol. 11, no. 1.					
		JOHN J. SAUK et al., "Binding motifs of CBP2 a potential cell surface target for carcinoma cells," Journal of Cellular Biochemistry, May 2000, pp. 251-263, vol. 78, no. 2.					
CY	i ! !	HEBERT CARLA et al., "Non-natural CBP2 binding peptides and peptomers modulate carcinoma cell adhesion and invasion," Journal of Cellular Biochemistry, 2001, pp. 145-154, vol. 82, no. 1.					
<u>C7</u>							

Examiner Signature	Chris	price	Date Considered	2	16	06	
<u></u>		Y			,		

EXAMINER Initial if reference considered. Abother or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Cificer. U.S. Patent and Trademark Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached